Gaining market access for new drug therapies is a fast-moving target.
Overcoming hurdles to market access is no small matter. Increasingly, cost-effectiveness and cost-containment are trumping safety and efficacy.
Forward-thinking biopharma is looking for new ways to anticipate the criteria (we call it “context”), against which their next drug will be evaluated by agencies / payers for reimbursement.
Let Context Matters put you in control of your blueprint for market access with the right data and technology.